# US 2022/0033857 A1 · Editing of haemoglobin genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033857 A1
- Document ID: US20220033857A1
- Status: Published application
- Kind: A1
- Application number: 17/278,679
- Filed: 2019-09-25
- Published: 2022-02-03
- Earliest claimed: 2018-09-26
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: James DAVIES; Douglas HIGGS; Mohsin BADAT
- Web page: https://patentgrep.com/patent/US20220033857A1

## CPC

- C12N 15/907: {in mammalian cells}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 38/42: Haemoglobins; Myoglobins
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 14/805: Haemoglobins; Myoglobins
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a process for producing a modified nucleic acid, wherein the nucleic acid comprises a mutant haemoglobin B (HBB) gene encoding a mutant Hb-β polypeptide. The process comprises using a base editor, preferably with a gRNA, to edit the mutant HBB gene to change a first (mutant) codon in that gene into a second, non-wild-type codon, wherein the Hb-β polypeptide encoded by that edited HBB gene has a non-wild-type, yet phenotypically-viable, amino acid sequence. The invention also provides a population of isolated haematopoietic stem cells, the stem cells comprising edited HBB genes.

## Claims

### Claim 1

A process for producing a modified nucleic acid molecule, the process comprising the steps:
(a) contacting a nucleic acid molecule comprising a mutant HBB gene encoding a mutant Hb-β polypeptide with a base editor, wherein the mutant HBB gene comprises a first non-wild-type codon coding for a first non-wild-type amino acid; and
(b) incubating the mutant HBB gene and base editor under conditions such that the base editor is targeted to the nucleotide sequence of the first non-wild-type codon and wherein the base editor edits one or more nucleotides in the first non-wild-type codon to produce a second non-wild-type codon which codes for a second non-wild-type amino acid, thereby producing a modified nucleic acid molecule comprising an edited HBB gene which encodes an edited Hb-β polypeptide,
wherein the edited Hb-β polypeptide has a non-wild-type, yet phenotypically-viable, amino acid sequence.

### Claim 2 (depends on 1)

A process as claimed in claim 1, wherein:
Step (a) comprises contacting a nucleic acid molecule comprising a mutant HBB gene encoding a mutant Hb-β polypeptide with a base editor and a gRNA, wherein the mutant HBB gene comprises a first non-wild-type codon coding for a first non-wild-type amino acid and wherein the gRNA is capable of targeting the base editor to the nucleotide sequence of the first non-wild-type codon of the mutant HBB gene; and
Step (b) comprises incubating the mutant HBB gene, base editor and gRNA under conditions such that the gRNA targets the base editor to the nucleotide sequence of the first non-wild-type codon and wherein the base editor edits one or more nucleotides in the first non-wild-type codon to produce a second non-wild-type codon which codes for a second non-wild-type amino acid, thereby producing a modified nucleic acid molecule comprising an edited HBB gene.

### Claim 3 (depends on 1)

A process as claimed in claim 1, wherein the HBB gene is a mammalian gene, or a human gene.

### Claim 4 (depends on 1)

The process as claimed in claim 1, wherein mutant HBB gene consists of or comprises a nucleotide sequence which encodes an amino acid sequence having 90-99.5%, or 95-99.5% sequence identity to SEQ ID NO: 2.

### Claim 5 (depends on 4)

The process as claimed in claim 4, wherein the nucleotide sequence at the codon which corresponds to codon 7 in SEQ ID NO: 1 codes for lysine or valine; and/or the nucleotide sequence at the codon which corresponds to codon 27 in SEQ ID NO: 1 codes for lysine.

### Claim 6 (depends on 5)

The process as claimed in claim 5, wherein the nucleotide sequence at the first non-wild-type codon which corresponds to codon 7 in SEQ ID NO: 1 is AAG or GTG; and/or the nucleotide sequence at the first non-wild-type codon which corresponds to codon 27 in SEQ ID NO: 1 is AAG.

### Claim 7

The process as claimed in wherein the base editor is a programmable nucleic acid binding protein (or an impaired CRISPR-Cas9 mutant, which is capable of being targeted to a target DNA sequence.

### Claim 8 (depends on 7)

The process as claimed in claim 7, wherein the base editor is an adenine deaminating editor.

### Claim 9 (depends on 2)

The process as claimed in claim 2, wherein:
(i) the guide RNA sequence for editing codon 7 is an 18-22 nucleotide guide RNA which is complementary to a nucleotide sequence located in SEQ ID NO: 15, wherein the wild-type complement of codon 7 (CTC) is replaced by CAC; or
(ii) the guide RNA sequence for editing codon 27 is an 18-22 nucleotide guide RNA which is located in SEQ ID NO: 16, wherein the wild-type codon 27 (GAG) is replaced by AAG; or
(iii) the guide RNA sequence for editing codon 7 is an 18-22 nucleotide guide RNA which is located in SEQ ID NO: 17, wherein the wild-type of codon 7 (GAG) is replaced by AAG.

### Claim 10

The process as claimed in wherein the edited HBB gene consists of or comprises:
(i) a nucleotide sequence having 90-99.9% nucleotide sequence identity to SEQ ID NO: 1 or a nucleotide sequence encoding an amino acid sequence having 95-99.5% amino acid sequence identity to SEQ ID NO: 2; and wherein
(ii) the nucleotide sequence at the codon which corresponds to codon 7 in SEQ ID NO: 1 codes for glycine or alanine; and/or the nucleotide sequence at the codon which corresponds to codon 27 in SEQ ID NO: 1 codes for glycine.

### Claim 11 (depends on 1)

The process as claimed in claim 1, wherein:
(i) the position of the first non-wild-type codon is codon 7, the wild-type codon at this position is GAG (glutamate), the first non-wild-type (mutant) codon sequence is AAG (lysine), the base editor is an adenine base editor and the second non-wild-type codon is GGG (glycine); or
(ii) the position of the first non-wild-type codon is codon 7, the wild-type codon at this position is GAG (glutamate), the first non-wild-type (mutant) codon sequence is GTG (valine), the base editor is an adenine base editor and the second non-wild-type codon is GCG (alanine); or
(iii) the position of the first non-wild-type codon is codon 27, the wild-type codon at this position is GAG (glutamate), the first non-wild-type (mutant) codon sequence is AAG (lysine), the base editor is an adenine base editor and the second non-wild-type codon is GGG (glycine).

### Claim 12 (depends on 1)

The process as claimed in claim 1, which additionally includes, prior to Step (a), the step of obtaining a sample of haematopoietic stem cells from a subject, or from a human subject, wherein the stem cells comprise nucleic acid molecules comprising mutant HBB genes.

### Claim 13 (depends on 1)

The process as claimed in claim 1, which additionally comprises, prior to Step (a), the step of modifying the nucleotide sequences of one or more PAM sites in the vicinity of the first non-wild-type codon in order to increase efficiency of the base-editing process.

### Claim 14 (depends on 1)

The process as claimed in claim 1, wherein the process is performed on haematopoietic stem cells which have previously been obtained from a first subject, or from a human subject, wherein the stem cells comprise nucleic acid molecules comprising mutant HBB genes.

### Claim 15 (depends on 14)

The process as claimed in claim 14, the process additionally comprises the subsequent step of introducing a population of haematopoietic stem cells comprising modified nucleic acid molecules comprising edited HBB genes, optionally after expansion of the cells, into a second subject, wherein the first and second subjects are the same or related subjects.

### Claim 16

A population of isolated cells comprising haematopoietic stem cells or progenitor cells comprising edited HBB genes, the edited HBB genes comprising:
(i) a nucleotide sequence having 90-99.9% nucleotide sequence identity to SEQ ID NO: 1 or a nucleotide sequence encoding an amino acid sequence having 95-99.5% amino acid sequence identity to SEQ ID NO: 2; and wherein
(ii) the nucleotide sequence at the codon which corresponds to codon 7 in SEQ ID NO: 1 codes for glycine or alanine; and/or the nucleotide sequence at the codon which corresponds to codon 27 in SEQ ID NO: 1 codes for glycine.

### Claim 17 (depends on 16)

The population of isolated cells as claimed in claim 16, wherein the population of isolated cells comprises at least 20% haematopoietic stem cells or progenitor cells having modified nucleic acid molecules comprising edited HBB genes, or at least 40%, at least 60%, at least 80% or 100% haematopoietic stem cells or progenitor cells having modified nucleic acid molecules comprising edited HBB genes.
